Galmed Pharmaceuticals
GLMD

$0.31

2.44%

Market Cap: 2M

About: Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.

Employees: 8

0

Funds holding %

of 6,702 funds

–

Analysts bullish %

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

0% more funds holding

Funds holding: 13 [Q4 2023] → 13 (+0) [Q1 2024]

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

9.82% less ownership

Funds ownership: 14.35% [Q4 2023] → 4.53% (-9.82%) [Q1 2024]

77% less capital invested

Capital invested by funds: $249K [Q4 2023] → $57.6K (-$191K) [Q1 2024]

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 4

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for GLMD.

See Analyst Rankings

Financial journalist opinion

Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024

Now could be a great time for investors to consider stacking up on penny stocks. These companies often have significant growth potential.

Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023

TEL AVIV, Israel , April 4, 2024 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, with the U.S. Securities and Exchange Commission (the "SEC").

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023

Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis

TEL AVIV, Israel , March 15, 2024 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases announced today the grant of a European patent related to the use of a combination of Aramchol and Resmetirom (MGL-3196, REZDIFFRA) for the treatment of NASH/MASH and liver fibrosis.

Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis

Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study

TEL AVIV, Israel , Nov. 20, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, announced today a delay of at least 6 months in the initiation of its Primary Sclerosing Cholangitis (PSC) Ph 2a Study.

Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study

See News Rankings